Completed PHASE4 INTERVENTIONAL 2-arm NCT00562107

Evaluation of the SafeR Mode in Patients With a Dual Chamber Pacemaker Indication (ANSWER)

Sponsor: LivaNova

Conditions Assess the Benefits From the AAISafeR/SafeR Algorithm of Symphony 2550 or REPLYTM DR in a Wide Range of Pacemaker Patients.

Interventions Symphony DR 2550 and REPLY DR cardiac pacemakers

Updated 6 times since 2017 Last updated: Sep 26, 2014 Started: Dec 31, 2007 Primary completion: Mar 31, 2011 Completion: Apr 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Assess the Benefits From the AAISafeR/SafeR Algorithm of Symphony 2550 or REPLYTM DR in a Wide Range of Pacemaker Patients. and is currently completed. LivaNova leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Dec 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

LivaNova

Data source: LivaNova

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amiens, France , Ashford, United Kingdom , Berlin, Germany , Bernau, Germany , Braunschweig, Germany , Brighton, United States , Béthune, France , Chieti, Italy , Conegliano, Italy , Essen, Germany and 27 more locations